• Vacunación contra el polio

Poliomyelitis, commonly called polio, is a highly infectious disease, caused by the poliomyelitis virus. The vast majority of poliovirus infections do not produce symptoms, but 5 to 10 out of 100 people infected with polio may have some flu-like symptoms. In 1 in 200 cases, the virus destroys parts of the nervous system, causing permanent paralysis in the legs or arms. Although very rare, the virus can attack the parts of the brain that help you breathe, which can cause death.

Although the last confirmed case of poliomyelitis from wild poliovirus in the Region of the Americas occurred in 1991, the threat continues. Despite efforts to eradicate it, there continues to exist children with permanent paralysis due to this virus in some Asian countries. Because of the risk of importation, the main risk factor for children under 5 years of age to acquire this disease is low vaccination coverage. 

Key facts

 

FAQs

Poliomyelitis, commonly called polio, is a highly infectious disease, caused by the poliomyelitis virus. The vast majority of poliovirus infections do not produce symptoms, but 5 to 10 out of 100 people infected with polio may have some flu-like symptoms. In 1 in 200 cases, the virus destroys parts of the nervous system, causing permanent paralysis in the legs or arms. Although very rare, the virus can attack the parts of the brain that help you breathe, which can cause death.

The virus is usually transmitted from person to person, from the feces of an infected individual, that reach the mouth of another susceptible individual. In some cases, the source of the infection may be water or food contaminated with feces from infected people. Transmission from respiratory secretions has also been described. Because a large proportion of infected people do not have symptoms, the hygiene measures necessary to prevent transmission may not be taken into account with the required importance.

People under the age of 15 who are not vaccinated against polio are at increased risk of polio; among them, those under the age of five are more susceptible. This risk increases when, in places where this person lives or visits, there are others not vaccinated against polio. In these environments, poor hygiene conditions further increase the chances of becoming infected with the poliovirus.

Polio should be suspected in unvaccinated or partially vaccinated children against polio with flu-like symptomatology (fever, muscle aches, headaches, lack of appetite), and who appear to recover and feel better; but after 2 to 5 days afterward they develop a headache, fever, severe muscle aches, involuntary muscle movements and tingling sensation in the legs or arms. One to two days later, the decrease in strength in the legs or arms appears, and the difficulty of walking. The decrease in strength progresses rapidly to paralysis, which is usually uneven among affected members.

Polio can cause permanent paralysis. Cases have been reported of individuals who fully recovered, but 15 to 40 years later developed postpolio syndrome, in which muscle aches, limb weakness and new episodes of paralysis occur again. It has been reported that 2 to 10 out of 100 children with paralytic polio die because paralysis affects the muscles that help to breathe.

To identify the poliovirus, a stool sample from each probable case should be tested in the laboratory, the sample should be collected within 14 days of the onset of paralysis. In the lab, the sample is inoculated in cell cultures where the virus can infect and replicate. This isolated virus is subsequently typified by molecular assays and genetic sequencing tests.

There are many infectious and non-infectious diseases that can cause paralysis, and therefore be mistaken for polio, including Guillaín-Barré syndrome, bumps or traumas of nerves in the spine or major nerves, and spinal tumors. Doctors will run various tests to rule out these diseases that may be mistaken for polio.

 

There is no antiviral or medicine that stops the progression of paralysis.

The best way to avoid infection is by vaccinating against polio. This vaccination is intended for children under 5 years of age. It is best to complete the vaccination schedule recommended by your country's health authorities in a timely manner. For a child to gain poliovirus immunity, several doses of the vaccine are required.

Two types of polio vaccines are used in the Region of the Americas: oral attenuated vaccine (OPV) and injected inactivated vaccine (IPV). The OPV vaccine contained all three types of poliovirus, 1, 2 and 3. Following the declaration of eradication of wild poliovirus type 2, in 2016, serotype 2 was removed from the vaccine and only the OPV vaccine with serotypes 1 and 3, known as bOPV, continued to be used. Gradually, countries are replacing the bOPV vaccine with the IPV vaccine.

Yes, polio vaccines are very safe and effective in protecting against polio. 

Most people vaccinated against polio have no side effects. The vaccine injected alone has in very rare cases caused mild redness or temporary induration at the site of administration. Allergic reactions associated with vaccines have also been reported.

The oral polio vaccine contains live viruses that have been attenuated to remove the ability to cause paralysis. In children vaccinated with the oral vaccine, attenuated viruses reproduce and persist in their intestines for up to six weeks, and are then excreted into the environment. These vaccine viruses can reach other susceptible children and provide protection. This is known as herd immunity. However, in places where polio vaccination coverage is low, these viruses can often be transmitted among unvaccinated, or partially vaccinated, children. In very rare cases these multiple transmissions can cause viruses to mute or change their genetic characteristics and can regain their ability to produce paralysis. This allows the occurrence of cases with paralysis derived from the polio vaccine.

In people with some primary impairments of their immunity, who have received attenuated poliovirus from the oral vaccine, there is a risk that poliovirus will continue to excrete for long periods of time, implying that the virus continues to replicate or multiply in the intestines. This can cause changes or mutations in viruses. In very rare cases this has allowed them to regain the ability to produce paralysis. Although no secondary cases of paralytic polio have been identified to people with primary immunodeficiencies, due to the excretion of poliovirus with genetic mutations, there is a risk of spread in susceptible communities, which could lead to a paralytic polio outbreak.

Because the inactivated polio vaccine contains dead virus segments, these viruses do not have the ability to replicate or multiply in the individual, so it has not been associated with cases of paralytic polio derived from the vaccine.

The best way to prevent polio is through vaccination. The inactivated vaccine, while protecting the recipient, cannot reproduce in the intestine. This prevents the obtaining of intestinal immunity, which is provided by the attenuated oral vaccine. This intestinal immunity helps prevent wild polioviruses from spreading. On the other hand, intestinal reproduction facilitates herd immunity, which occurs when an attenuated poliovirus is transmitted from a vaccinated person to a susceptible person. Other advantages of the oral vaccine against the inactivated vaccine are its easy application and low cost. These prerogatives lead to the decision to use the oral vaccine in public health programs, generating population immunity and cutting off the transmission of wild poliovirus in infected communities.

WHO position papers on Poliomyelitis vaccine


 See more

Relevant Information

A key step in global polio eradication is the destruction of all polioviruses, or their containment at essential facilities. In December 2014, WHO published the third Global Action Plan (GAPIII) for poliovirus containment aimed at minimizing the risks associated with the likelihood of accidental or deliberate poliovirus release from facilities after the eradication of wild polioviruses and the sequential cessation of routine OPV use.

Aligned with GAPIII, the Regional Plan consists of three phases relating to international polio eradication milestones: phase I, containment preparation; phase II, poliovirus type 2 containment period; and phase III, final poliovirus containment.

The Regional GAPIII survey was sent out in August 2015. Some countries have already adapted this format and are collecting the information electronically or by post. The survey is currently underway in other countries.

Essential activities that countries of the Region should carry out in phase I:

  • Appoint a national poliovirus containment coordinator
  • Draw up a list of laboratories and facilities
  • Conduct a survey of laboratories and facilities
  • Draw up an inventory of laboratories and facilities that stock infectious and/or potentially infectious material
  • Destroy or transfer infectious and potentially infectious poliovirus material
  • Prepare final containment report on all wild poliovirus in January 2016, and on Sabin type 2 poliovirus in August 2016.

Countries must inform PAHO about their decision to have a designated essential poliovirus facility, which in turn must inform WHO, so that WHO can initiate the containment certification process.

Regional Plan for Containment of Poliovirus in the Americas(GAPIII)

Statement of responsibility for collections of samples with OPV2/Sabin2 PIM

 

Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses (PIM), 2018

 

PIM Guidance - Annex 2 Country or Area-specific Poliovirus Data, November 2018

 

Resolution WHA71.16 Poliomyelitis Containment of Polioviruses, May 2018

 

Resolution WHA71.16 Key containment activities

Following the recommendation of the Technical Advisory Group on Vaccine-Preventable Diseases (TAG) of the Pan American Health Organization/World Health Organization (PAHO/WHO) issued in March and July 2017, regarding the implementation of fractional doses of the inactivated poliovirus vaccine (fIPV) in the routine immunization schedule, the PAHO/WHO Immunization Unit has prepared the following materials to support countries in planning and implementation process of fIPV.

Practical Guide: Implementation of fractional doses of IPV vaccine (fIPV)

 

PAHO Brochure: World Polio Day 2017

 

Magnet: Multi-dose Open Vial Policy for WHO prequalified vaccines

 

 

Video: Administration of fractional dose of IPV vaccine (fIPV)

 

A key factor in the success of polio eradication is a rapid and effective response to any poliovirus detection event or polio outbreak caused by the importation of poliovirus or the emergence of a vaccine-derived poliovirus.

To guide countries on the development of a response plan for a poliovirus or polio outbreak event, the World Health Organization (WHO) prepared a document on standard operating procedures (PNT), incorporating lessons learned from previous outbreak response efforts and describing guidelines for responding to detection events and outbreaks caused by serotype poliovirus 1 , 2 and 3. Based on THE SOPs developed by WHO, the Pan American Health Organization (PAHO/WHO) prepared this document, considering all the key elements of a response plan and is aimed at the technical teams of the countries of the Region, who will coordinate the national response to poliovirus detection events or polio outbreaks.

Standard Operating Procedures: Responding to a poliovirus event or outbreak

Check List - Components for the National Plan

This document sets out strategic guidelines for responding to events or outbreaks caused by any type of poliovirus, however, its recommendations focus primarily on the response to type 2 polioviruses, in the first 12 months since the withdrawal of OPV2, from May 2016 to April 2017, and are mainly aimed at countries that made use of the trivalent oral polio vaccine against polio , in the 12 months prior to the change in tOPV to bOPV.

Whereas in the response to the detection of poliovirus, common steps should be taken to any type of poliovirus and specific steps, depending on the strain detected and its origin; this document has been organized according to the type of poliovirus detected and the source of the sample into three large blocks:

  • Poliovirus type 2,
  • Poliovirus type 1 o 3 and
  • Any poliovirus in environmental samples. 

Complete this form for any person aged 15 years with Acute Flaccid Paralysis (AFP), and for a person of any age in whom polio is suspected.

Regional Commission for the Certification of Polio Eradication in the Region of the Americas (RCC)

 

The Regional Certification Commission carries out a careful and detailed review of the documentation that each country presents to demonstrate its progress and contributions to the eradication of polio. Additionally, every country of the Region established a National Certification Committees (NCC) whose task is to collect, review and validate the information provided by the Ministries of Health, and send the documentation to the RCC.

The Commission is made up of seven recognized experts in the Region in the fields of public health, epidemiology, pediatrics, virology, infectious diseases, and immunology. The members of the RCC are appointed by the Director of PAHO/WHO for a period of 3 years, and may be reelected for additional periods, in accordance with the requirements of the Polio Eradication Endgame Strategic Plan.

The responsibilities of the RCC are to:

  1. Assess the fulfillment of polio eradication certification requirements in the Region of the Americas, as defined by the Global Certification Commission (GCC), with particular consideration of immunization coverage, surveillance, containment, risk assessment, risk mitigation, and outbreak preparedness;
  2. Define, and update as necessary, the documentation required from each country of the Region to demonstrate maintenance of polio-free status;
  3. Review updated polio eradication documentation from each country of the Region on an annual basis and report those findings and required actions to the PAHO Regional Director and to the National Certification Committee in each country;
  4. Conduct site visits to countries, as required, to review or verify their polio-free status (including laboratory containment of wild, VDPV, and Sabin polioviruses);
  5. Work closely with National Certification Committees and provide recommendations to fulfill the requirements for global certification;
  6. Review and validate national reports and documentation on laboratory containment of all polioviruses in order to assess progress to minimize poliovirus facility associated risk and recommend actions necessary to achieve laboratory containment goals within the Region.

National Certification Committees (NCCs) are independent committees made up of leading experts in relevant disciplines (in the fields of public health, immunization, epidemiology, pediatrics, infectious diseases, neurology and virology), appointed by the national government in consultation with the PAHO/WHO Regional Office.

Roles and Responsibilities:

  1. Assess the fulfillment of polio eradication certification requirements in their country, as defined by the Global Certification Commission (GCC) and the Regional Certification Commission, and respond to the following questions:
  2. Population Immunity: Is polio vaccination coverage high enough to prevent the circulation of wild poliovirus or emergence of circulating vaccine derived poliovirus (cVDPV)?
  3. Surveillance: Is polio surveillance sensitive enough to rapidly and reliably detect an imported wild poliovirus or VDPV should it emerge?
  4. Containment: Has the country minimized the risks of a facility-associated reintroduction of poliovirus for facilities collecting, handling or storing materials infectious or potentially infectious for polioviruses?
  5. Risk Assessment: Has the country conducted a risk assessment down to the subnational level?
  6. Risk Mitigation: Has the country developed an appropriate risk mitigation plan?
  7. Event and Outbreak Preparedness: Is the country adequately prepared to respond to an event or outbreak if one were to occur?
  8. Polio-free Status Assessment: Is the committee firmly convinced that the country was free of polio during the reporting period?
  9. Review and approve the polio eradication documentation requested from the RCC on an annual basis and submit the documentation with a signed approval form and letter to the RCC, through the PAHO country office.
  10. Review and approve the national response plan for an event or outbreak of polio.
  11. Review and approve the reports and documentation on containment of all polioviruses to assess progress to minimize poliovirus facility associated risk and recommend actions necessary to achieve containment goals.
  12. Work closely with national authorities on the implementation of RCC recommendations to maintain polio-free status in the country and to fulfill the requirements for global polio eradication certification.
  13. Review and respond to letters sent by the RCC with country specific recommendations.
  14. When the time comes, review and approve the final certification report and any other required documentation to the RCC.

VIDEOS

Virtual experience - Celebrating 25 years certified polio free!

SOCIAL MEDIA CARDS

Latest news

Stories

Documents

Communication Materials

Epidemiological Updates and Alerts

Mandates and Strategies

All

Events

More information